Payment overview · 2025
General Payments
$789.68
13 reported records · 4 companies
Healthcare provider profile · identity verified
Nathaniel Lee Griffith, DO
Allopathic & Osteopathic Physicians|Internal Medicine · EL PASO, TX · NPI 1811918766
Verified facts
What the public records show
CMS Open Payments records show Nathaniel Lee Griffith, DO received $789.68 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $470.19 | 59.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.40 | 26.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.76 | 12.1% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.33 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $789.68 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $249.21 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $220.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $149.82 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $104.62 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $103.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.93 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.16 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.18 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 113 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
113 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 592 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 399 | 126 |
| Losartan Potassium | Losartan Potassium | 347 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 98 |
| Tizanidine Hcl | Tizanidine Hcl | 330 | 130 |
| Pravastatin Sodium | Pravastatin Sodium | 322 | 102 |
| Metformin Hcl Er | Metformin Hcl | 316 | 99 |
| Omeprazole | Omeprazole | 276 | 85 |
| Gabapentin | Gabapentin | 239 | 74 |
| Celecoxib | Celecoxib | 230 | 84 |
| Meloxicam | Meloxicam | 218 | 78 |
| Lorazepam | Lorazepam | 205 | 27 |
| Metformin Hcl | Metformin Hcl | 192 | 61 |
| Lisinopril | Lisinopril | 186 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 58 |
| Azithromycin | Azithromycin | 174 | 127 |
| Trazodone Hcl | Trazodone Hcl | 169 | 52 |
| Tramadol Hcl | Tramadol Hcl | 168 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 167 | 41 |
| Telmisartan | Telmisartan | 161 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 42 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 144 | 55 |
| Chlorthalidone | Chlorthalidone | 143 | 45 |
| Famotidine | Famotidine | 140 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 41 |
| Alprazolam | Alprazolam | 136 | 24 |
| Jardiance | Empagliflozin | 124 | 29 |
| Montelukast Sodium | Montelukast Sodium | 122 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 37 |
| Raloxifene Hcl | Raloxifene Hcl | 117 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 56 |
| Farxiga | Dapagliflozin Propanediol | 113 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 35 |
| Donepezil Hcl | Donepezil Hcl | 102 | 32 |
| Carvedilol | Carvedilol | 92 | 33 |
| Trulicity | Dulaglutide | 84 | 16 |
| Lamotrigine | Lamotrigine | 83 | 15 |
| Alendronate Sodium | Alendronate Sodium | 80 | 28 |
| Eliquis | Apixaban | 80 | 19 |
| Bupropion Xl | Bupropion Hcl | 73 | 13 |
| Mirtazapine | Mirtazapine | 71 | 16 |
| Baclofen | Baclofen | 70 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 22 |
| Mounjaro | Tirzepatide | 66 | 15 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Finasteride | Finasteride | 63 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 14 |
| Allopurinol | Allopurinol | 54 | 18 |
| Spironolactone | Spironolactone | 54 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 37 |
| Glipizide | Glipizide | 48 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 14 |
| Lactulose | Lactulose | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 18 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 15 |
| Prednisone | Prednisone | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Furosemide | Furosemide | 34 | 15 |
| Naproxen | Naproxen | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 24 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $789.68 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AVYCAZ, BREZTRI, EMBLAVEO, FARXIGA, JARDIANCE, MOUNJARO, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error